Search results for "Pulmonary and Respiratory Medicine"
showing 10 items of 1498 documents
221 Better Event-Free Survival in Ambulatory Heart Transplant (HTx) Candidates Who Are Physically Active and in Good Mood
2012
(pre-Group1 89.6 6.1 x pre-Group2 89.3 6.9, p 0.8; 1yr97.6 1.1 x 97.1 1.5, p 0.3; 2yr96.8 2.3 x 97.0 1.1,p 0.9,in %); MIP (pre64.0 23.9 x 65.5 24.2, p 0.8; 1yr94.9 25.2 x 98.5 15.6, p 0.7; 2yr93.4 26.6 x 101.3 12.6, p 0.7) and MEP (pre-92 29.1 x 86.5 27.1, p 0.5; 1yr 99.2 28.5 x 104.9 16.4,p 0.9; 2yr 103.14 25 x 105.6 16.4, p 0.7,in cmH2O) and 6MWT (pre-428 137.4 x 411.2 113.9, p 0.5; 1yr 629.2 91.26 x 659.2 93.5, p 0.3; 2yr 645.9 91.5 x 686.6 98.6, p 0.2,in meters). Conclusions: Our findings indicate that unsupervised rehabilitation may represent an alternative in the management of post lung transplant patients.
162 Medical and Psychosocial Predictors of Mechanical Circulatory Support Device Implantation in the Waiting for a New Heart Study
2011
286: Waiting for a new heart: Early experience from a prospective multi-site study of psychosocial and medical predictors of pre-transplant outcomes
2007
593: Gender Differences in One-Year Waiting List Outcomes in Heart Transplant Candidates: Results from the Waiting for a New Heart Study
2009
443: Social Isolation and Depression as Predictors of 12 Month Outcomes in the Waiting for a New Heart Study
2009
Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database
2016
s S233 218 (82%) patients received pooled platelet transfusion -median (IQR) 1(1-2) U. 209 (79%) and 129 (49%) patients received fresh frozen plasma (FFP) and cryoprecipitate with a median (IQR) of 3(2-4) and 0(0-0) U respectively. Conclusion: Rate and volume of transfusion of blood products compare favourably with centres performing surgery off CPB or on ECMO. Requirement for ECMO particularly for BTT, but also PGD is associated with high transfusion requirements.
469: Prospective, randomized, multicenter trial comparing conversion to a CNI-free regimen (MMF & sirolimus) vs. a CNI-reduced, MMF-based immunos…
2007
Endovascular treatment of acute bleeding complications in traumatic aortic rupture and aortobronchial fistula.
2001
Objective: Herein we report our experience in placement of endovascular stentgrafts in the descending aorta in patients with acute bleeding complications due to traumatic rupture or aortobronchial fistula. Methods: Six patients (one woman, five men, mean age 47 ^ 19 years) were treated from September 1995 to February 2000 by implantation of endovascular stentgrafts in the descending aorta. Indications included traumatic ruptures of the aortic isthmus (na 3) and aortobronchial fistulas (na 3). All procedures were performed under general anaesthesia. The implants were introduced under fluoroscopic guidance via the aorta (na 1), the iliac (na 4) or femoral (na 2) artery, respectively. Results:…
Social robots and therapeutic adherence: a new challenge in pediatric asthma?
2020
Social Robots are used in different contexts and, in healthcare, they are better known as Socially Assistive Robots. In the context of asthma, the use of Socially Assistive Robots has the potential to increase motivation and engagement to treatment. Other positive roles proposed for Socially Assistive Robots are to provide education, training regarding treatments, and feedback to patients. This review evaluates emerging interventions for improving treatment adherence in pediatric asthma, focusing on the possible future role of social robots in the clinical practice.
P131 Efficacy of tiotropium and olodaterol combination in patients with COPD on β-blockers: Abstract P131 Table 1
2015
Rationale The efficacy and safety of a new once-daily combination with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β2-agonist, was established for the treatment of chronic obstructive pulmonary disease (COPD) in the TONADO studies ([NCT01431274][1]; [NCT01431287][2]). This analysis evaluates the efficacy of the combination in a subpopulation of patients receiving β-blockers in these studies. Methods Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O (2.5/5 μg; 5/5 μg; via Respimat® inhaler) once daily compared to the monocomponents. Key primary end-point data for the combined a…